Enzo Biochem (ENZ) Launch of Test for Measuring Risk of Colorectal Cancer Underscores Growing Role of Molecular Diagnostics  
4/10/2012 10:27:55 AM

NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE: ENZ) today announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical community.